 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- IMP7068 / IMPACT Therap
Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors (Valencia Auditorium - Hall 10) - Jul 27, 2023 - Abstract #ESMO2023ESMO_1377;
P1
80mg was defined as a potential PR2D in 3/4 schedule, and a second potential RP2D is being explored in 5/2 schedule. RP2D for IMP7068 will be determined soon.
- adavosertib (AZD1775) / AstraZeneca
Discovery and development of a potent and highly selective WEE1 inhibitor IMP7068 (Section 31; Poster Board #4) - Mar 14, 2023 - Abstract #AACR2023AACR_4526;
P1
Anti-tumor efficacy of IMP7068 has been demonstrated in mice CDX models of colorectal LoVo, non-small cell lung cancer NCI-H1299 and a PDX model of uterine UT5318 with good dose-response tumor inhibition and tolerability. IMP7068 is currently in a phase I study to evaluate its safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT04768868).
- || IMP7068 / IMPACT Therap
Enrollment change, Monotherapy, Metastases: WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 26, 2022
P1, N=350, Recruiting, Sponsor: Impact Therapeutics, Inc.
IMP7068 is currently in a phase I study to evaluate its safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT04768868). N=150 --> 350
- |||| IMP7068 / IMPACT Therap
#ESMO22 so high frequency ≥Gr3 QT prolonged with WEE1 inhibitor IMP7068 (Twitter) - Sep 13, 2022
- IMP7068 / IMPACT Therap
Safety, pharmacokinetic (PK), and pharmacodynamic profiles of the WEE1 inhibitor IMP7068 in patients (pts) with advanced solid tumors (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2486;
P1
Dose escalation including a BID regimen is under evaluation. The RP2D is expected to be determined soon, and multiple expansion cohorts (including uterine serous carcinoma and biomarker-selected populations) are planned for initiation later this year.
- IMP7068 / IMPACT Therap
A phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5249;
P1
IMP7068 was well-tolerated with no DLTs, and conferred a meaningful PD effect and preliminary antitumor activity at doses of up to 160 mg in pts with advanced solid tumors. Dose escalation to establish the recommended phase 2 dose and/or maximum tolerated dose is continuing.
- ||| IMP7068 / IMPACT Therap
Enrollment open, Monotherapy, Metastases: WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 21, 2021
P1, N=150, Recruiting, Sponsor: Impact Therapeutics, Inc.
Dose escalation to establish the recommended phase 2 dose and/or maximum tolerated dose is continuing. Not yet recruiting --> Recruiting
- ||| IMP7068 / IMPACT Therap
New P1 trial, Monotherapy, Metastases: WEE1: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 23, 2021
P1, N=150, Not yet recruiting, Sponsor: Impact Therapeutics, Inc.